Publications by authors named "Iradj Sobhani"

Background: Sunitinib, a multitarget tyrosine kinase inhibitor, showed encouraging antitumor activity and manageable toxicity in patients with advanced midgut neuroendocrine tumors (NETs) in earlier results from phase I and II trials.

Patients And Methods: In this phase II trial, patients with a nonresectable grade 1 or 2 midgut progressive NET and Eastern Cooperative Oncology Group performance status 0-1 were randomly assigned 1:1 to receive 37.5 mg sunitinib or a placebo, combined with 120 mg lanreotide autogel every 28 days.

View Article and Find Full Text PDF

Introduction And Aim: Simultaneous positron emission tomography/magnetic resonance imaging (PET-MRI) combines the high sensitivity of PET with the high specificity of MRI and is a tool for the assessment of gastroenteropancreatic neuroendocrine neoplasms (G-NENs). However, it remains poorly evaluated with no clear recommendations in current guidelines. Thus, we evaluated the prognostic impact of PET-MRI in G-NEN patients.

View Article and Find Full Text PDF

Colorectal cancer (CRC) stands as a significant global health concern, ranking second in mortality and third in frequency among cancers worldwide. While only a small fraction of CRC cases can be attributed to inherited genetic mutations, the majority arise sporadically due to somatic mutations. Emerging evidence reveals gut microbiota dysbiosis to be a contributing factor, wherein polyketide synthase-positive (pks+ ) plays a pivotal role in CRC pathogenesis.

View Article and Find Full Text PDF
Article Synopsis
  • Intratumoral bacteria, specifically Colibactin-producing (CoPEC) strains, are linked to tumor heterogeneity and cancer recurrence by creating a low-immunity environment in right-sided colorectal tumors.
  • These bacteria foster lipid accumulation in cancer cells, which helps them survive and resist chemotherapy, correlating with worse survival rates in advanced-stage colorectal cancer patients.
  • Targeting the metabolic changes induced by CoPEC with specific inhibitors has shown potential in restoring chemotherapy sensitivity, suggesting a new approach to improve treatment outcomes for patients colonized by these bacteria.
View Article and Find Full Text PDF

Purpose: Through a pilot study, we performed whole gut metagenomic analysis in 17 Lynch syndrome (LS) families, including colorectal cancer (CRC) patients and their healthy first-degree relatives. In a second asymptomatic LS cohort (n=150) undergoing colonoscopy-screening program, individuals with early precancerous lesions were compared to those with a normal colonoscopy. Since bacteria are organized into different networks within the microbiota, we compared related network structures in patients and controls.

View Article and Find Full Text PDF

Background: Gastric Mucosa Associated Lymphoid Tissue lymphoma (GML) development is triggered by Helicobacter pylori (H. pylori) infection. Little is known about the impact of H.

View Article and Find Full Text PDF

Aim: Patients with Crohn's disease (CD) are at higher risk of small bowel adenocarcinoma (SBA). We aimed to identify radiological predictors of SBA in CD.

Methods: We conducted a retrospective case-control study at two tertiary inflammatory bowel disease centers and identified CD patients diagnosed with SBA between 2003 and 2019.

View Article and Find Full Text PDF

Recently, an intestinal dysbiotic microbiota with enrichment in oral cavity bacteria has been described in colorectal cancer (CRC) patients. Here, we characterize and investigate one of these oral pathobionts, the Gram-positive anaerobic coccus . We identified two phylotypes (A and B) exhibiting different phenotypes and adhesion capabilities.

View Article and Find Full Text PDF
Article Synopsis
  • GEP-NETs can negatively impact patients' quality of life, and providing adequate information may enhance their treatment adherence and overall wellbeing.
  • The OPERA study aimed to assess changes in patients' perceptions of the information they received about their condition and treatment after starting lanreotide (LAN) for GEP-NETs, comparing data collected at the beginning and six months later.
  • Results showed no significant changes in patients’ perceptions of information regarding their disease, treatment, or supportive care after six months, indicating that the information provided by physicians was likely adequate from the start.
View Article and Find Full Text PDF

(1) Background: Anastomotic biliary stricture (ABS) is a well-known complication of liver transplantation which can lead to secondary biliary cirrhosis and graft dysfunction. The goal of this study was to evaluate the long-term outcomes of endoscopic metal stenting of ABS in the setting of deceased donor liver transplantation (DDLT). (2) Methods: Consecutive DDLT patients with endoscopic metal stenting for ABS between 2010 and 2015 were screened.

View Article and Find Full Text PDF

Background: There is no standard second-line treatment after platinum-etoposide chemotherapy for gastroenteropancreatic neuroendocrine carcinoma. We aimed to evaluate the efficacy of FOLFIRI plus bevacizumab, and FOLFIRI alone, in this setting.

Methods: We did a randomised, non-comparative, open-label, phase 2 trial (PRODIGE 41-BEVANEC) at 26 hospitals in France.

View Article and Find Full Text PDF

Purpose: Evidence suggests that patients with obstructive sleep apnea (OSA) are at increased risk of suffering from periodontitis, a chronic inflammatory disease of the tooth-supporting tissues associated with a dysbiotic oral microbiota. This systematic review aims to explore the current literature about the composition of the oral microbiota in patients with OSA compared to those without OSA.

Methods: Medline, Embase, and Cochrane Library were searched in May 2022 to identify original articles investigating the oral microbiota composition and/or oral microbiome (any microbiological technique) of patients with OSA (adults or children) vs.

View Article and Find Full Text PDF

Purpose: Robotic surgery has been progressively implemented for colorectal procedures but is still limited for multiquadrant abdominal resections. The present study aims to describe our experience in robotic multiquadrant colorectal surgeries and provide a systematic review and meta-analysis of the literature investigating the outcomes of robotic total proctocolectomy (TPC), total colectomy (TC), subtotal colectomy (STC), or completion proctectomy (CP) compared to laparoscopy.

Methods: At our institution 16 consecutive patients underwent a 2- or 3-stage totally robotic total proctocolectomy (TPC) with ileal pouch-anal anastomosis.

View Article and Find Full Text PDF

To assess the effectiveness and safety of rituximab alone or in combination with chlorambucil for the treatment of translocation (11;18)-negative gastric MALT lymphoma, we included 71 patients in a retrospective case-control study, 54 treated with rituximab alone and 17 with combination therapy. There was no difference between the groups in complete remission or overall response rates at weeks 25 and 52. After a median follow-up period of 5.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigated the presence of the opportunistic pathogen subspecies in stool samples from patients with normal colonoscopy, colorectal adenomas, and colorectal cancer.
  • Notable findings included a significantly higher prevalence of this pathogen in colorectal cancer patients, along with increased levels of toxinogenic bacteria and other CRC-associated bacteria in their stools.
  • The research suggests that the presence and levels of these bacteria change during the stages of colorectal cancer, with the specific pathogen identified as significant even at the early adenoma stage.
View Article and Find Full Text PDF

Despite the advances in surgical techniques and perioperative care, the complication rates after colorectal cancer surgery have remained stable. Recently, it has been suggested that colon microbiota may be implicated in several pathways that can lead to impaired colonic homeostasis and, thereby, to the development of complications after colorectal surgery. The aim of this study was to evaluate the potential impact of colonic dysbiosis on postoperative course.

View Article and Find Full Text PDF

Colorectal cancer (CRC) is the second most common cause of cancer deaths in men and women combined [...

View Article and Find Full Text PDF

Colorectal carcinoma (CRC) is a common disease, the incidence of which is increasing according to Western lifestyle; it remains to have a poor prognosis. Western nutriments are presumed to induce mild inflammation within the colonic mucosa, resulting in the accumulation of DNA alterations in colonocytes through a multistage carcinogenesis process. This suggests that most CRCs are related to the environment.

View Article and Find Full Text PDF

Background: In France, it is mandatory that gastroenterology fellows have mastered the basic level of endoscopy by the end of training. The aim of this study was to assess improvement in the quality of fellows' endoscopy training in France during the last four years.

Methods: All fellows in France in training were eligible for participation.

View Article and Find Full Text PDF
Article Synopsis
  • Bile duct injury (BDI) is a serious complication following cholecystectomy, with incidences ranging from 0.4% to 1.5%, potentially leading to significant long-term health issues for patients.
  • Early recognition of BDIs, whether during surgery or soon after, is crucial for effective treatment, as delayed diagnoses can complicate management and outcomes.
  • The 2020 World Society of Emergency Surgery (WSES) guidelines provide evidence-based recommendations on preventing, diagnosing, and managing BDIs, covering risk reduction strategies, classification, intraoperative management, and postoperative care.
View Article and Find Full Text PDF

Extrahepatic cholangiocarcinoma (CCA) accounts for 3% of digestive cancers. The role of biliary microbiota as an environment-related modulator has been scarcely investigated in CCA, and the putative impact of associated diseases has not been yet assessed. We characterized the biliary microbiota in CCA patients in order to identify a specific CCA-related dysbiosis.

View Article and Find Full Text PDF

Background: There are few data regarding multiple switching from the originator Infliximab to its biosimilars.

Aim: To assess outcomes and patient perspectives in a prospective manner after double switching from Infliximab to the biosimilars CT-P13 and SB2.

Methods: A total of 158 consecutive patients with inflammatory bowel disease (IBD) receiving CT-P13 maintenance therapy were switched to SB2 and followed for 54 weeks.

View Article and Find Full Text PDF

An increasing body of evidence highlights the role of fecal microbiota in various human diseases. However, more than two-thirds of fecal bacteria cannot be cultivated by routine laboratory techniques. Thus, physicians and scientists use DNA sequencing and statistical tools to identify associations between bacterial subgroup abundances and disease.

View Article and Find Full Text PDF

Colorectal cancer (CRC) is the second most common cause of cancer deaths in men and women combined. Colon-tumor growth is multistage and the result of the accumulation of spontaneous mutations and epigenetic events that silence tumor-suppressor genes and activate oncogenes. Environmental factors are primary contributors to these somatic gene alterations, which account for the increase in incidence of CRC in western countries.

View Article and Find Full Text PDF

Introduction: Rituximab is a standard treatment for gastric mucosa-associated lymphoid tissue (MALT) lymphoma (GML). We sought to compare the effectiveness and safety of subcutaneous and intravenous rituximab in a retrospective case-control study.

Patients And Methods: All consecutive patients with GML treated with subcutaneous rituximab between January 2017 and December 2018 were included and compared to 3 matched control patients (based on Ann Arbor classification, presence of t(11;18) translocation, history of treatment, and type of current treatment) treated with intravenous rituximab between January 2000 and December 2018.

View Article and Find Full Text PDF